CTLA4 and neoplasm: Although the combination of anti-PD-1/PD-L1 and anti-CTLA-4 agents has demonstrated superior efficacy over monotherapy in multiple tumor types, its clinical benefits in specific malignancies such as HNSCC require further precise delineation.